Categories: News

AlzeCure Presents at Vator Healthcare Innovation Summit on October 7

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

STOCKHOLM, SE / ACCESSWIRE / September 30, 2021 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)

AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company is participating at the Vator Healthcare Innovation Summit at Epicenter Stockholm on October 7 at 10:20 CEST, where CEO Martin Jönsson will present the company’s latest developments.

The presentation will be live streamed and held in English. Register for the event at: https://vatorsecurities.se/event/vator-securities-healthcare-innovation-summit/. The presentation will also be available afterwards on AlzeCure’s website https://www.alzecurepharma.se/en/presentations-and-interviews/.

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease and comprises two drug candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se.

Image Attachments

Martin Jönsson CEO AlzeCure Pharma

Attachments AlzeCure presents at Vator Healthcare Innovation Summit on October 7

SOURCE: AlzeCure Pharma

View source version on accesswire.com:
https://www.accesswire.com/666224/AlzeCure-Presents-at-Vator-Healthcare-Innovation-Summit-on-October-7

Staff

Recent Posts

Amazfit Introduces Balance 2 Smartwatch and Helio Strap for Smarter Training, Better Recovery and Peak Performance

Amazfit Smart Wearables Require No Additional SubscriptionMILPITAS, Calif.--(BUSINESS WIRE)--#DiscoverAmazing--Amazfit, a leading global smart wearable brand…

2 hours ago

Amazfit Introduces Balance 2 Smartwatch and Helio Strap for Smarter Training, Better Recovery and Peak Performance

Amazfit Smart Wearables Require No Additional SubscriptionMILPITAS, Calif.--(BUSINESS WIRE)--#DiscoverAmazing--Amazfit, a leading global smart wearable brand…

2 hours ago

NanoVibronix’s ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement

Dual-System Agreement Highlights Transition Towards Advanced Bedside NavigationTYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or…

2 hours ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)…

2 hours ago

SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy

Cincinnati Children’s Hospital Medical Center Discusses QUELIMMUNE Therapy Adoption A Father and Patient Describe Their…

2 hours ago

Innovate GBM Rings the NASDAQ Closing Bell in Honor of Brain Tumor Patients and Community

Innovate GBM Community Innovate GBM’s Community Members gather at the NASDAQ Closing Bell Ceremony—united in…

2 hours ago